Clinical trials located in

Kielce

Kielce city is located in Poland. Currently, 20 clinical trials are being conducted in this city.

Kielce, nestled in south-central Poland, is a city rich in history and natural beauty. Founded in the 11th century, it boasts a remarkable blend of architectural styles, from medieval to modern. The city is surrounded by the picturesque Świętokrzyskie Mountains, making it a hub for outdoor activities. Kielce’s cultural heritage is highlighted by the 17th-century Palace of the Kraków Bishops, a testament to its historical significance. Additionally, it played a pivotal role in the industrial development of the region, with its Kielce Trade Fairs known nationally.

  • CT-EU-00116671

    Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    • mRNA-4157/V940
    • placebo
    • Pembrolizumab
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • A comprehensive evaluation of retatrutide in obesity and associated comorbidities

    This study evaluates the effectiveness and safety of a new drug, retatrutide, in individuals with obesity or overweight, including those with knee osteoarthritis or obstructive sleep apnea. Lasting about 89 weeks, the trial involves randomized assignment of participants to either receive retatrutide or a placebo. The main goals are to observe changes in body weight, knee pain in osteoarthritis, and sleep apnea severity. The study also examines various secondary outcomes like changes in BMI, waist circumference, and blood pressure. The trial aims to provide new insights into weight management and associated health conditions, offering hope for improved treatments.

    • Retatrutide
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    • Vibostolimab
    • Pembrolizumab
  • Comparing remibrutinib and teriflunomide for Multiple Sclerosis

    This study is all about comparing two treatments for relapsing multiple sclerosis (RMS)—a medicine called remibrutinib and another one called teriflunomide. Initially, researchers will do what’s known as a ‘double-blind, which means neither the participants nor the researchers know which treatment the participant takes. This part of the study will involve about 800 people and will go for up to 30 months. After this, the participants can continue the study openly taking remibrutinib for up to 5 years. The study will measure things like how often the MS relapses, changes in disability scale, amount of new lesions, changes in blood markers, walking and arm function, mood, pain, and deviations in various health parameters. There will be a lesser version trial simultaneously, with results from both pooled for analysis.

    • Teriflunomide
    • Remibrutinib
  • Comparing treatments in multiple myeloma: talquetamab in combination with other medication

    This study aims to explore the combined effects of talquetamab, daratumumab, pomalidomide, and dexamethasone for treating relapsed or refractory multiple myeloma. One group of patients will receive talquetamab subcutaneous in combination with daratumumab and pomalidomide. The second group will receive talquetamab subcutaneous in combination with daratumumab. The patients of the third group will be treated with daratumumab subcutaneous in combination with pomalidomide and dexamethasone. The research is divided into three phases: screening, treatment, and post-treatment follow-up. The study will assess efficacy, safety, and monitoring various health indicators at specific time points. The results of this combination therapy will be compared to choose the safest and the most effective treatment. The overall duration of the study is expected to be up to 6 years and 6 months.

    • Pomalidomide
    • Talquetamab
    • Dexamethasone
    • Daratumumab
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Long-term study on ofatumumab effects in relapsing multiple sclerosis atients

    This study is being conducted to assess the safety of long-term usage of a drug called ofatumumab in patients with relapsing multiple sclerosis, a condition that can disrupt the nervous system. As part of the study, an investigation is being carried out to determine the ease of administration and the efficacy of the drug. Individuals who have previously participated in other studies involving ofatumumab for multiple sclerosis are eligible to enroll in this study. A sub-study is also being conducted to examine the impact of ofatumumab on the body’s response to specific vaccines and an antigen known as KLH. Antigens are substances capable of triggering the production of antibodies in the body. Progress will be assessed based on the annual frequency of disease relapses and changes in disability, using the EDSS scale. EDSS evaluates factors such as vision, brain function, and walking ability.

    • Tetanus toxoid (TT) containing vaccine (Td, Tdap)
    • 13-valent pneumococcal conjugate vaccine (13-PCV)
    • 23-valent pneumococcal polysaccharide vaccine (23-PPV)
    • Seasonal Quadrivalent influenza vaccine
    • Keyhole limpet hemocyanin (KLH) neo-antigen
    • Ofatumumab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Evaluating two drug combinations for advanced breast cancer

    This study is examining two different drug combinations for treating a specific type of breast cancer. The primary aim is to assess the comparative effectiveness and safety of these combinations. One combination uses the drugs lasofoxifene and abemaciclib, and the other uses fulvestrant and abemaciclib. The patients for this trial are men and women who have already been treated for breast cancer that has spread or cannot be removed by surgery, is positive for estrogen receptors (ER+), does not over-produce a growth factor (HER2-), and has a specific genetic mutation (ESR1).

    • Fulvestrant
    • Abemaciclib
    • Lasofoxifene
  • Impact of apalutamide on hormone-sensitive prostate cancer

    This is a study on prostate cancer, particularly patients suffering from a high-risk, hormone-sensitive form. The researchers want to check how adding a drug called apalutamide to the regular treatment can affect the cancer. The standard treatment includes radiotherapy and a drug that blocks the hormone responsible for cancer growth, known as LHRH. This study will check if adding apalutamide can delay the cancer from spreading or help patients live longer. The researchers will track disease progress using a special imaging test called PSMA-PET. They will also monitor changes in PSA, a protein made by the prostate that rises when cancer is present. Other important measures include how long it takes for the cancer to spread and the general rate of survival.

    • Apalutamide
  • Testing the efficacy of teclistamab vs other drugs for relapsed or refractory multiple myeloma treatment

    The study is evaluating a treatment for a blood cancer known as multiple myeloma. Two different treatments are being compared to assess their effectiveness in both slowing down the disease and minimizing side effects. The first treatment involves a single medicine called teclistamab, while the second offers a choice between two combinations of multiple medicines (either PVd – pomalidomide, bortezomib, dexamethasone or Kd – carfilzomib, dexamethasone). Both treatments have been previously administered to individuals with similar conditions. Individuals who have undergone prior treatment, including the use of an anti-CD38 monoclonal antibody and lenalidomide, but experienced a recurrence or lack of resolution of the disease, are eligible to participate in this study. The objective is to determine the duration it takes for the disease to progress under different treatments. Additionally, the study will monitor changes in health and potential medication-related issues through regular check-ups.

    • Carfilzomib
    • Pomalidomide
    • Teclistamab
    • Dexamethasone
    • Bortezomib
  • Inhaler treatment study for Mycobacterium Avium complex lung infection

    This study is for adults with lung infections caused by Mycobacterium avium complex. It tests a new inhalation treatment, ALIS (amikacin liposome inhalation suspension), in combination with standard drugs, azithromycin and ethambutol. The aim is to see if ALIS improves respiratory symptoms better than the standard treatment alone. Participants will receive either ALIS or a placebo, along with the standard drugs. The study focuses on safety, symptom improvement, and overall health impact. This research is important for finding more effective treatments for these challenging lung infections.

    • ALIS (amikacin liposome inhalation suspension)
    • Azithromycin
    • Ethambutol
  • Comparing darolutamide with standard therapy in hormone sensitive prostate cancer

    This study explores a combination therapy using darolutamide and androgen deprivation therapy (ADT) for men with high-risk biochemical recurrence of prostate cancer. ADT are treatments that block androgens production in the body. The trial aims to determine if this combination prolongs the time without cancer worsening or leading to death compared to ADT alone. Participants will be randomly assigned to receive either the combination treatment or a placebo with ADT for 24 months. The study will track cancer progression, overall health, and any side effects, offering potential advancements in prostate cancer treatment.

    • Darolutamide/BAY1841788
  • Study new combination therapy in advanced lung cancer

    This study is about testing a new drug mix to help people with advanced lung cancer (NSCLC) that doesn’t have special gene changes. The research aims to determine whether a combination of three drugs, namely Datopotamab Deruxtecan (Dato-DXd), Durvalumab, and Carboplatin, demonstrates superior efficacy compared to an alternative drug mixture. The people in this study have stage IIIB, IIIC, or IV lung cancer. They will be split in two groups. One group will get Datopotamab Deruxtecan, Durvalumab, and Carboplatin. The other group gets Pembrolizumab and some specific chemo drugs. he primary objective is to assess whether the new three-drug combination can effectively delay cancer growth and extend overall survival time.

    • Datopotamab deruxtecan (Dato-DXd)
    • Pemetrexed
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Durvalumab
    • Paclitaxel
  • Evaluating depemokimab’s efficacy in severe asthma treatment

    This trial studies the long-term effects of depemokimab in adults and adolescents with severe eosinophilic asthma. Participants who previously joined specific depemokimab studies (206713 or 213744) continue treatment to assess long-term safety and efficacy. The trial monitors adverse events and checks for anti-drug antibodies to evaluate the drug’s sustained effectiveness. The study aims to ensure the safety and prolonged benefit of depemokimab for severe asthma management. It is vital for advancing asthma treatment and improving patient quality of life.

    • GSK3511294 (Depemokimab)
  • Investigating a new inhaler’s impact: comparative study in asthma treatment

    The study is designed to assess whether PT010, a new inhaler, can be beneficial for adults and teenagers with poorly managed asthma. PT010 comprises three active ingredients: budesonide, glycopyrronium, and formoterol. The comparative analysis aims to determine the effectiveness and safety of PT010 in comparison to another inhaler containing budesonide and formoterol, as well as the widely used Symbicort inhaler. The study will span from 24 to 52 weeks and involve approximately, 2200 participants from various locations. The primary focus will be on the improvement of lung function within 24 weeks, alongside evaluating the reduction in the frequency of asthma attacks and its impact on quality of life and respiratory control.

    • Symbicort
    • Budesonide/formoterol fumarate (BFF pMDI)
    • budesonide/glycopyrronium/formoterol (BGF MDI)
  • Study of drug combinations for advanced lung cancer

    This study is about a new combination of medical treatments, Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab and Carboplatin, intended to help people with severe lung cancer (NSCLC). This type of lung cancer lacks specific alterations in its genes that can be targeted by other forms of treatment. The scientists are testing whether this new combination of medicines can be better than another common treatment combination, Pembrolizumab and platinum-based chemotherapy. The researchers will measure the time people can live without their disease getting worse (Progression Free Survival or PFS) and the total time they survive (Overall Survival or OS) to check which treatment is superior. These periods will be monitored with special criterias set up by the medical community. The study will also observe how long people respond to the treatment (Duration of Response or DoR) and how many have an observable reaction to the treatment (Objective Response Rate or ORR). Additionally, they will be analyzing the concentration of Dato-DXd and other components in the blood to inspect the body’s interaction with this treatment.

    • Datopotamab deruxtecan
    • Pemetrexed
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Durvalumab
    • Paclitaxel
  • Assessing the efficacy of atuliflapon in uncontrolled asthma relief

    This study is looking at atuliflapon, a new medication, for adults with moderate to severe uncontrolled asthma. The trial is a Phase 2 study, which means it’s testing how effective and safe atuliflapon is. About 1,102 adults who are already using asthma medications will be part of this study. They will take atuliflapon or a placebo once a day for 12 weeks. The goal is to see if atuliflapon can help reduce asthma attacks and improve breathing in people whose asthma isn’t well-controlled with their current treatments.

    • Atuliflapon

See more clinical trials in other cities in Poland:

.